Intellia Therapeutics (NTLA) Accumulated Depreciation (2015 - 2025)
Intellia Therapeutics (NTLA) posted quarterly Accumulated Depreciation of $58.6 million for Q4 2025, up 17.94% year-over-year from $49.7 million in Q4 2024, and up 17.94% quarter-over-quarter from $49.7 million in Q4 2024.
Intellia Therapeutics (NTLA) Accumulated Depreciation (2015 - 2025) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Accumulated Depreciation for 11 consecutive years, with $58.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 17.94% year-over-year to $58.6 million; the TTM figure through Dec 2025 stood at $58.6 million (up 17.94% YoY), while the FY2025 annual figure was $58.6 million, up 17.94% from the prior year.
- Accumulated Depreciation climbed to $58.6 million in Q4 2025 per NTLA's latest filing, from $49.7 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $58.6 million in Q4 2025 and bottomed at $26.1 million in Q4 2021.
- Historically, Accumulated Depreciation has averaged $41.5 million across 5 years, with a median of $39.9 million in 2023.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation jumped 35.09% — and 2025, when it rose 17.94%.
- Intellia Therapeutics' Accumulated Depreciation stood at $26.1 million in 2021, then climbed by 27.13% to $33.2 million in 2022, then climbed by 20.07% to $39.9 million in 2023, then climbed by 24.66% to $49.7 million in 2024, then grew by 17.94% to $58.6 million in 2025.
- Business Quant data shows NTLA's Accumulated Depreciation at $58.6 million in Q4 2025, $49.7 million in Q4 2024, and $39.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.61 Mn |
| Dec 31, 2024 | 49.69 Mn |
| Dec 31, 2023 | 39.86 Mn |
| Dec 31, 2022 | 33.20 Mn |
| Dec 31, 2021 | 26.11 Mn |
| Dec 31, 2020 | 19.33 Mn |
| Dec 31, 2019 | 13.87 Mn |
| Dec 31, 2018 | 8.61 Mn |
| Dec 31, 2017 | 4.33 Mn |
| Dec 31, 2016 | 1.43 Mn |
| Dec 31, 2015 | 331,000.00 |